Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 12:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Treatment of Bleeding Clear all
Not yet recruiting No phase listed Observational

Rapid Evacuation and Access of Cerebral Hemorrhage Registry

NCT07651631
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 23, 2026, 12:43 PM EDT
Completed Phase 1 Interventional

Mesenchymal Stem Cells Therapy in Patients With Recent Intracerebral Hemorrhage

NCT03371329
View directory record Official record
Conditions
Hemorrhagic Stroke, Intracerebral Hemorrhage
Interventions
MSC
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Jul 23, 2026, 12:43 PM EDT
Terminated Phase 3 Interventional

Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor

NCT04867837
View directory record Official record
Conditions
Acute Major Bleeding
Interventions
Octaplex
Drug
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
10
States / cities
Torrance, California • Gainesville, Florida • West Palm Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 23, 2026, 12:43 PM EDT
Completed Phase 3 Interventional Results available

Endometrial Safety Study

NCT00522873
View directory record Official record
Conditions
Postmenopause
Interventions
0.25mg DRSP / 0.5mg E2 (BAY86-4891), 0.5mg NETA / 1.0mg E2 (Activella)
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Chandler, Arizona • San Diego, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Jul 23, 2026, 12:43 PM EDT
Completed Phase 2 Interventional

A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

NCT05714969
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura (TTP)
Interventions
TAK-755
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
12
States / cities
Gainesville, Florida • Boston, Massachusetts • Minneapolis, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 23, 2026, 12:43 PM EDT
Terminated Phase 3 Interventional Results available

Initial Treatment of Patients With Immune Thrombocytopenic Purpura

NCT00991939
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura
Interventions
Dexamethasone USP Micronized, Prednisone
Drug
Lead sponsor
Carelon Research
Other
Eligibility
15 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
18
States / cities
New Orleans, Louisiana • Baltimore, Maryland • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Jul 23, 2026, 12:43 PM EDT
Completed Phase 4 Interventional Results available

MRI and Neurodevelopment in Preterm Infants Following Administration of High-Dose Caffeine

NCT00809055
View directory record Official record
Conditions
Apnea of Prematurity, Intraventricular Hemorrhage, Brain Injury
Interventions
Caffeine citrate
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
24 Weeks to 30 Weeks
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Jul 23, 2026, 12:43 PM EDT
Completed Not applicable Interventional Results available

The SQUID Trial for the Embolization of the Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma (STEM)

NCT04410146
View directory record Official record
Conditions
Subdural Hematoma, Chronic
Interventions
SQUID Embolization, SQUID Embolization and Surgical Evacuation, Surgical Evacuation, Standard Medical Management
Device · Procedure · Other
Lead sponsor
Balt USA
Industry
Eligibility
30 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
25
States / cities
Phoenix, Arizona • Tucson, Arizona • Riverside, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 23, 2026, 12:43 PM EDT
Completed Phase 3 Interventional Results available

A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A

NCT03528551
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A
Interventions
Turoctocog alfa pegol
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Male only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
18
States / cities
Phoenix, Arizona • Long Beach, California • Iowa City, Iowa + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Jul 23, 2026, 12:43 PM EDT
Terminated Phase 2 Interventional Results available

Safety Study of Nicardipine to Treat Cerebral Vasospasm

NCT01810302
View directory record Official record
Conditions
Cerebral Vasospasm
Interventions
Nicardipine hydrochloride, Preservative-free normal saline
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Jul 23, 2026, 12:43 PM EDT
Recruiting Not applicable Interventional

Lumbar Drain vs Extraventricular Drain to Prevent Vasospasm in Subarachnoid Hemorrhage

NCT03065231
View directory record Official record
Conditions
Vasospasm, Intracranial, Subarachnoid Hemorrhage
Interventions
Extraventricular Drain, Lumbar Drain
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 110 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Jul 23, 2026, 12:43 PM EDT
Recruiting No phase listed Observational

Middle Meningeal Artery Embolization (MMAE) Outcomes for Chronic Subdural Hematoma (cSDH)

NCT06181994
View directory record Official record
Conditions
Chronic Subdural Hematoma
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
15
States / cities
Coral Gables, Florida • Jacksonville, Florida • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 23, 2026, 12:43 PM EDT
Completed Not applicable Interventional Results available

Same-session MR-only Simulation and Treatment With MRI-guided Adaptive Palliative RadioTherapy

NCT03824366
View directory record Official record
Conditions
Malignancy, Metastasis, Hemoptysis, Gastrointestinal Bleeding, Pelvic Bleeding, Superior Vena Cava Syndrome, Mediastinal Disease
Interventions
Volumetric MR imaging, Radiation therapy
Device · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Jul 23, 2026, 12:43 PM EDT
Completed No phase listed Observational

Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study

NCT03292666
View directory record Official record
Conditions
Venous Thromboembolism, Anticoagulants and Bleeding Disorders
Interventions
Oral Anticoagulant
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
39,603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
2
States / cities
Oakland, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Jul 23, 2026, 12:43 PM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

NCT00061022
View directory record Official record
Conditions
Cerebral Stroke, Stroke, Acute, Cerebrovascular Stroke, Ischemic Attack, Transient
Interventions
NXY-059
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
98
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 95 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2010 · Synced Jul 23, 2026, 12:43 PM EDT
Withdrawn Phase 4 Interventional

Is Using Fondaparinux (Blood Thinner) to Treat Lung Clot Cheaper Than Traditional Therapy

NCT00377091
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Fondaparinux
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Jul 23, 2026, 12:43 PM EDT
Completed Phase 2 Interventional

Treatment of Post-Punch Biopsy Bleeding in Apixaban-Treated Patients Using Self-Administered BXP154B

NCT06205615
View directory record Official record
Conditions
Wound Bleeding
Interventions
BXP154B, Placebo, Punch Biopsy
Drug · Procedure
Lead sponsor
Bio 54, LLC
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Jul 23, 2026, 12:43 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly

NCT06082843
View directory record Official record
Conditions
Hypertension, Portal, Liver Cirrhosis
Interventions
Placebo, Avenciguat
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Pasadena, California • Rialto, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Jul 23, 2026, 12:43 PM EDT
Completed Phase 4 Interventional Results available

NOrth American Study for the Treatment of Recurrent epIstaxis With DoxycycLine: The NOSTRIL Trial

NCT04167085
View directory record Official record
Conditions
Epistaxis
Interventions
Doxycycline, Placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Jul 23, 2026, 12:43 PM EDT
Terminated Phase 2 Interventional

Use of Activated Recombinant Human Factor VII in Cardiac Surgery

NCT00154427
View directory record Official record
Conditions
Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass
Interventions
activated recombinant human factor VII
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
18
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jul 23, 2026, 12:43 PM EDT
Completed Phase 3 Interventional Results available

A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood

NCT05147662
View directory record Official record
Conditions
Treatment of Bleeding, Prophylaxis of Bleeding, Hemophilia A, Children
Interventions
Damoctocog alfa pegol (Jivi, BAY94-9027)
Biological
Lead sponsor
Bayer
Industry
Eligibility
7 Years to 11 Years · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 23, 2026, 12:43 PM EDT
Terminated Not applicable Interventional Results available

Doppler-Guided Uterine Artery Occlusion (DUAO) Device for Fibroid Related Bleeding

NCT00496080
View directory record Official record
Conditions
Menorrhagia, Uterine Fibroids
Interventions
Doppler-Guided Uterine Artery Occlusion Device (DUAO)
Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
9
States / cities
Phoenix, Arizona • Fort Lauderdale, Florida • Southfield, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Jul 23, 2026, 12:43 PM EDT
Withdrawn Phase 4 Interventional

The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy

NCT01042574
View directory record Official record
Conditions
Hypertension, Intracranial Hemorrhage, Subarachnoid Hemorrhage
Interventions
Clevidipine butyrate
Drug
Lead sponsor
Methodist Healthcare - Memphis
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Jul 23, 2026, 12:43 PM EDT
Completed Not applicable Interventional Results available

Safety and Effectiveness of the Jada System in Treating Primary Postpartum Hemorrhage

NCT02883673
View directory record Official record
Conditions
Postpartum Hemorrhage
Interventions
Jada System
Device
Lead sponsor
Alydia Health
Industry
Eligibility
18 Years and older · Female only
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
15
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Jul 23, 2026, 12:43 PM EDT